v3.26.3
Liquidity and Going Concern
3 Months Ended
Sep. 30, 2026
Liquidity and Going Concern  
Liquidity and Going Concern

Note 2 – Liquidity and Going Concern

The Company’s condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2026 of approximately $162.8 million and a net loss of approximately $5.7 million and net cash used in operating activities of approximately $3.6 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future.

As of September 30, 2026, the end of the reporting period, the Company had approximately $2.6 million in cash and cash equivalents. The Company’s liabilities at September 30, 2026 were approximately $3.2 million, including accounts payable of approximately $528 thousand payable to third parties, accounts payable to related parties of approximately $704 thousand, accrued expenses of approximately $719 thousand, and accrued expenses – related party of approximately $1.2 million. Management believes that the Company’s cash and cash equivalents balance of approximately $2.6 million at September 30, 2026, and the Company’s availability, under its $3 million line of credit will be sufficient to fund the Phase II clinical trial for evaluation of NV-387 for the treatment of Ebola and also for the Phase II clinical trial for Mpox in DRC, but will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result substantial doubt exists about the Company’s ability to continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon controlling its overall expenses and identifying and securing additional financing.

The Company believes that it has several milestones including the anticipated successful completion of Phase II clinical trial of NV-387 as treatment for Mpox, and attendant top-line readout, and its recent commencement of Phase II Clinical Trials for treatment of Bundibugyo Ebola Virus. On or about August 4, 2026, the Company received regulatory approval to conduct this clinical trial from Autorité Congolaise de Réglementation Pharmaceutique (“ACOREP”), the pharmaceutical drug regulatory agency of the Democratic Republic of the Congo (“DRC”). The regulatory approval satisfied the conditions perfecting the Company’s financial commitment for the clinical trial. The Company has initiated the Phase IIA part of the trial. The trial is enrolling and is expected to continue to enroll persons exhibiting different disease severity levels.

The Company submitted an application for, “Orphan Drug Designations” (“ODD”) from the US FDA for three specific uses of NV-387, namely (1) NV-387 for Treatment of Mpox, (2) NV-387 for Treatment of Smallpox, and (3) NV-387 for Treatment of Measles. An ODD carries with it several benefits that include rapid FDA meetings, R&D tax breaks, and a Seven year exclusivity for the drug upon licensure. On April 27, 2026 the FDA granted the ODD to NV-387 for the treatment of Measles. In May 2026 the FDA granted the Rare Pediatric Disease Drug (RPDD) designation for NV-387 as a Treatment for Measles. We continuing to seek “Orphan Drug Designation” for the remaining two ODD applications for Mpox and Smallpox from the US FDA.

The Company plans to take advantage of the increased FDA interactions for filing appropriate Pre-IND applications and IND applications with the US FDA. We believe that the Mpox Phase II if successful, will likely enable a Phase II/III licensure clinical trial under the US FDA auspices upon completion, which may provide the shortest possible timeline for NV-387 licensure.

Further, the regulatory timelines for these three orphan diseases are likely to be substantially shorter than, say RSV, COVID, or Influenza drug development. This is because in the case of rare and orphan diseases, there are inherent limitations on the clinical trial recruitment due to the small number of available subjects, and the clinical protocols are designed to take this into account. Smaller number of subjects usually makes a clinical trial go faster, except in cases where the incidence rate of the disease cannot support the required recruitment level.

The Company has planned a novel Phase II clinical trial for evaluating NV-387 as a first line, empiric therapy for any respiratory viral infection, in an adaptive, basket-style clinical trial design. We are in discussions to execute this clinical trial in India. In a single and relatively low cost clinical trial, we will be able generate substantial, statistically declarative information, regarding NV-387 as a treatment for (1) Influenza, (2) COVID, (3) RSV, (4) human MetaPneumovirus (hMPV), along with valuable information on effectiveness of NV-387 against many other respiratory infections including Adenoviruses, Enteroviruses, and others, depending upon the rates of incidence in the incoming patients. NV-387 can then progress towards licensure individually against RSV, Influenza, COVID, and other respiratory viruses under the US FDA and internationally.

The Company executes its plans in a manner consistent with available resources, which can lead to reshuffling of priorities in its programs. Nevertheless, the Company has in the past and will continue to progress towards its goal of revolutionizing antiviral therapeutics.

Management believes that as these various milestones are achieved, the Company would likely experience improvement in the liquidity of the Company’s stock, and such improvement, if any, would enhance the Company’s ability to raise funds on the public markets at terms that may be favorable to the terms offered at present.

Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, as well as debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations.

Management believes that it has on-going access to the capital markets including the “At-The-Market” (ATM) agreement with D. Boral Capital LLC, the Sales Agent.

There can be no assurance that the Company’s plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue that reaches a level sufficient to provide self-sustaining cash flows. There can be no assurance that the Company will be able to raise the necessary capital or that it will be on acceptable terms. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties.